The round featured corporate-backed venture firm Lux Capital and will support completion of phase 3 trials for a treatment aimed at dry eye disease.

US-based ophthalmic drugs developer Kala Pharmaceuticals closed an oversubscribed $68m series C round yesterday featuring Lux Capital, a venture capital firm backed by a range of unnamed corporations.

The round was led by VC firm Longitude Capital and included OrbiMed, Vivo Capital, Cam Capital, RA Capital Management, Wellington Management Company, Polaris Partners, Crown Venture Fund (CVF) and other, unnamed existing shareholders.

Founded in 2009 by Lux Capital, Kala is working on therapies for ocular diseases that affect the front…